There is no indication that Calquence capsules have been discontinued. Calquence (acalabrutinib) is an oral medication used to treat certain types of non-Hodgkin lymphoma, specifically mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [1].
When might Calquence lose patent protection?
The patent protection for Calqueness (acalabrutinib) is a key factor in its market availability and potential for generic competition. Information regarding patent expiry dates is crucial for understanding future market dynamics. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can provide insights into when exclusivity for drugs like Calquence might end [2].
What is Calquence used for?
Calquence is prescribed for adults diagnosed with mantle cell lymphoma (MCL) who have received at least one prior therapy [1]. It is also used for adults with previously treated or treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [1].
How does Calquence work?
Calquence is a Bruton's tyrosine kinase (BTK) inhibitor. BTK is a protein that plays a role in the growth and survival of certain white blood cells, including malignant B-cells. By inhibiting BTK, acalabrutinib disrupts signaling pathways essential for these cells, leading to their death [1].
What are the potential side effects of Calquence?
Common side effects associated with Calquence treatment can include low blood cell counts (anemia, thrombocytopenia, neutropenia), diarrhea, fatigue, muscle pain, bruising, headache, and upper respiratory tract infections [1]. More serious side effects may occur, and patients should discuss any concerns with their healthcare provider [1].
Are there other drugs like Calquence?
Acalabrutinib is part of a class of BTK inhibitors. Other drugs in this class, such as ibrutinib and zanubrutinib, are also used to treat similar hematologic malignancies [3]. Comparisons between these BTK inhibitors often focus on efficacy, safety profiles, and patient tolerability [3].
What is the regulatory status of Calquence?
Calquence is approved by regulatory agencies like the U.S. Food and Drug Administration (FDA) for its indicated uses in treating MCL and CLL/SLL [1]. These approvals are based on clinical trial data demonstrating the drug's safety and effectiveness.
Sources:
1. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/acalabrutinib
2. https://drugpatentwatch.com/
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689935/